Micro-biolytics
To simplify the process of chemical analytics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
N/A | Growth Equity VC | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (63 %) | 203 % | 56 % | (91 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 27 % | 7 % | (103 %) | 137 % | (115 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Established in 2001 as micro-biolytics GmbH, the Germany-based company now operates as CLADE GmbH. With a foundation spanning over two decades, the firm has cultivated deep expertise in solutions centered around Mid-Infrared (MIR) spectroscopy. CLADE operates primarily as a supplier and service provider to the biopharmaceutical and chemical industries, leveraging its proprietary technologies to support its partners.
The company's core business involves providing quality control for a range of materials, from basic chemical substances to complex biopharmaceutical products. This is accomplished through a combination of proprietary MIR-based spectroscopy, in-house software, and specialized algorithms. The foundational AquaSpec technology is a patented, sensitive spectroscopic method for analyzing aqueous or organic samples. micro-biolytics evolved this method to create fully automated analysis and evaluation systems suitable for industrial applications. Its offerings cater to pharmaceutical drug development, process control, and medical diagnostics.
The business model focuses on delivering a spectrum of services to the pharmaceutical sector. These services include the development of customized applications tailored to specific client needs, performing service measurements coupled with statistical data analysis, and integrating the AquaSpec technology directly into a client's production process. The company's team consists of over 60 experts from more than 10 nations, driving its functions from locations in Esslingen, Frankfurt, and Berlin.
Keywords: bio-analytics, MIR spectroscopy, quality control, biopharmaceutical services, chemical industry supplier, AquaSpec technology, process control, medical diagnostics, pharmaceutical development, spectroscopic analysis, automated analysis systems, data evaluation, industrial applications, Esslingen, chemical quality control, biopharma solutions, analytical services, proprietary algorithms, spectroscopy solutions, lab technology